arrow
S

Somnath Mukherjee

Oxford University Hospitals NHS Foundation Trust
H指数:28
被引数:3,496

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis

每日适应性MR引导立体定向消融再程放疗(re-SABR)在寡转移性肝癌中的应用:一项单机构回顾性分析

2025-11-190
OAAI
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
2024-09-010
PRE
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
2023-07-015
OAAI
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX , or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

吉西他滨联合卡培他滨、FOLFIRINOX或放化疗治疗边缘可切除胰腺癌患者的即刻手术比较 (ESPAC5): 一项四组、多中心、随机、2期临床试验

2023-02-01143
OAAI
Use of a non-endoscopic immunocytological device (Cytosponge™) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): A multicentre feasibility study
2022-11-014
OAAI
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes

TET2驱动GATA6的5hmc标记,并在表观遗传学上定义胰腺导管腺癌转录亚型

2021-08-0134
OA
Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial
2021-08-0111
OAAI